Press Releases Filter Filter Results Year 2024 (4) 2023 (5) 2022 (23) 2021 (17) 2020 (38) 2019 (36) 2018 (23) 2017 (25) 2016 (20) 2015 (25) 2014 (26) 2013 (31) 2012 (35) October 28, 2024 Impella ECP Pivotal Study Demonstrates Safety, Efficacy for Use in High-Risk PCI October 24, 2024 New Data at TCT 2024 Expands on Recently Published New England Journal of Medicine Randomized Controlled Trial Demonstrating a Survival Benefit from Impella Heart Pumps August 12, 2024 Abiomed Celebrates 25 Years of Heart Recovery with Impella® April 7, 2024 Randomized Controlled Trial Confirms Impella CP® Improves Survival in Heart Attack with Cardiogenic Shock November 27, 2023 First Patient Enrolled in Abiomed’s RECOVER IV Randomized Controlled Trial of Impella® as a Therapy for AMI Cardiogenic Shock October 23, 2023 Abiomed to Highlight Data Analysis Identifying Complex Clinical Profile of Patients Receiving Impella®-Supported HRPCI at TCT Symposium May 18, 2023 Analysis Showcases Potential for More Complete Revascularizations with Impella Compared to IABP during HRPCI April 24, 2023 Pivotal Impella ECP Study Expands Enrollment to Three New Jersey Hospitals February 24, 2023 Abiomed at CRT 2023: Benefits of Impella-Supported High Risk PCI and Impella Innovation December 22, 2022 Johnson & Johnson Completes Acquisition of Abiomed December 21, 2022 FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial December 5, 2022 First Patients in the World Treated with Impella RP Flex with SmartAssist November 1, 2022 Johnson & Johnson to Acquire Abiomed November 1, 2022 Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year October 31, 2022 Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure 1 2 3 4 …
